Ferraccioli GF - Search Results

1

Steroid sparing therapeutic approaches to polymyalgia rheumatica-giant cell arteritis. State of the art and perspectives.

Ferraccioli GF, Di Poi E, Damato R. Ferraccioli GF, et al. Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S58-60. Clin Exp Rheumatol. 2000. PMID: 10948766 Review.

2

Jaw and leg claudication in a patient with temporal arteritis, chronic sialoadenitis and previous hepatitis C virus infection.

Ferraccioli GF, Mariuzzi L, Damato R, Rocco M, Pirisi M, Beltrami CA. Ferraccioli GF, et al. Clin Exp Rheumatol. 1998 Jul-Aug;16(4):463-8. Clin Exp Rheumatol. 1998. PMID: 9706429 No abstract available.

3

Tumor necrosis factor-alpha gene polymorphism in severe and mild-moderate rheumatoid arthritis.

Fabris M, Di Poi E, D'Elia A, Damante G, Sinigaglia L, Ferraccioli G. Fabris M, et al. J Rheumatol. 2002 Jan;29(1):29-33. J Rheumatol. 2002. PMID: 11824966

4

Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis.

Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G. Fabris M, et al. J Rheumatol. 2002 Sep;29(9):1847-50. J Rheumatol. 2002. PMID: 12233877

5

Autoimmune connective tissue disease, chronic polyarthritides and B cell expansion: risks and perspectives with immunosuppressive drugs.

Ferraccioli GF, De Vita S, Casatta L, Damato R, Pegoraro I, Bartoli E. Ferraccioli GF, et al. Clin Exp Rheumatol. 1996 Jan-Feb;14 Suppl 14:S71-80. Clin Exp Rheumatol. 1996. PMID: 8722204 Review.

6

High dose intravenous immunoglobulin therapy for rheumatic diseases: clinical relevance and personal experience.

De Vita S, Ferraccioli GF, Di Poi E, Bartoli E, Bombardieri S. De Vita S, et al. Among authors: ferraccioli gf. Clin Exp Rheumatol. 1996 May-Jun;14 Suppl 15:S85-92. Clin Exp Rheumatol. 1996. PMID: 8828953 Review.

7

Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years.

Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Ferraccioli GF, et al. Rheumatology (Oxford). 2002 Aug;41(8):892-8. doi: 10.1093/rheumatology/41.8.892. Rheumatology (Oxford). 2002. PMID: 12154206 Clinical Trial.

8

Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial.

Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, De Marchi G, Fabris M. Ferraccioli GF, et al. Rheumatology (Oxford). 2002 Oct;41(10):1109-12. doi: 10.1093/rheumatology/41.10.1109. Rheumatology (Oxford). 2002. PMID: 12364628 Clinical Trial.

9

Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab.

Di Poi E, Perin A, Morassi MP, Del Frate M, Ferraccioli GF, De Vita S. Di Poi E, et al. Among authors: ferraccioli gf. Clin Exp Rheumatol. 2007 Jan-Feb;25(1):85-7. Clin Exp Rheumatol. 2007. PMID: 17417995 Clinical Trial.

10

Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: relationship with tristetraprolin expression.

Fabris M, Tolusso B, Di Poi E, Tomietto P, Sacco S, Gremese E, Ferraccioli G. Fabris M, et al. J Rheumatol. 2005 Jun;32(6):998-1005. J Rheumatol. 2005. PMID: 15940758

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

338 results

Search Page

Filters